My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Efalizumab Biosimilar, CD11a Monoclonal Antibody

Efalizumab Biosimilar, CD11a Monoclonal Antibody

Integrin, alpha L, antigen CD11A, p180, lymphocyte function-associated antigen 1, alpha polypeptide, ITGAL, LFA-1, LFA1A, integrin subunit alpha L

Catalog No. Product Name Size List Price (US$) Quantity
C045P Efalizumab Biosimilar, CD11a Monoclonal Antibody 1 mg 175.00
C045P Efalizumab Biosimilar, CD11a Monoclonal Antibody 5 mg 600.00
C045P Efalizumab Biosimilar, CD11a Monoclonal Antibody 20 mg 1600.00
C045P.05 Efalizumab Biosimilar, Endotoxin 0.05 EU/mg 5 mg 900.00
C045P.05 Efalizumab Biosimilar, Endotoxin 0.05 EU/mg 20 mg 2400.00
Description

C045P: Efalizumab Biosimilar, CD11a Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human CD11a monoclonal antibody efalizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade efalizumab biosimilar specifically binds to the human CD11a.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by efalizumab.
Form of Antibody: 0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin: <1 EU/mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade efalizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

Efalizumab Biosimilar uses the same protein sequences as the therapeutic antibody efalizumab.

Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.

Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.

Related Links

See our Privacy Policy